Whole Exome Sequencing Reveals Variant Associated with Spontaneous Intraabdominal Hemorrhage in Severe Acute Pancreatitis

Qiuyi Tang,Yue-Peng Hu,Qi Yang,Jing Zhou,Jing-Zhu Zhang,Jie Yang,Haibin Hao,Gang Li,Bai-Qiang Li,Lu Ke,Zhi-Hui Tong,Yu-Xiu Liu,Evan Yi-Wen Yu,Wei-Qin Li

DOI: https://doi.org/10.1101/2024.08.06.24311443

2024-08-07

Abstract:This study sought to identify genetic cause of spontaneous intraabdominal hemorrhage (SIH) in severe acute pancreatitis (SAP) to develop more effective treatment for this life-threatening complication. A four-phase study was conducted, leveraging a large-scale acute pancreatitis (AP) patients (n=600); the first phase involved whole-exome sequencing analyses, and identified specific exonic variant located in (i.e., rs1326680184) that was consistently associated with SIH; the second phase performed serum ELISA tests, and revealed that variant altered FCGBP level and further led to predisposition of SIH; the third phase conducted an i) experiment with a -knockdown mouse model, and demonstrated lower expression of led to more severe AP morphology and higher risk of hemorrhage; ii) experiment with -knockdown human vascular fibroblasts demonstrated that down-regulated expression could destabilize the vascular wall, and lead to vascular injury in SAP; the fourth phase compared variant carriers to non-carriers with clinical characteristics, and found variant associated with higher risks of poor complications and AP prognosis and enhanced the diagnostic capability as an indicator. These findings provide important insights into the underlying mechanism of SIH in SAP, and facilitate therapeutic development for AP prognosis and critical care in an early phase.

Gastroenterology

What problem does this paper attempt to address?

The main objective of this paper is to identify the genetic causes of Spontaneous Intraabdominal Hemorrhage (SIH) in patients with Severe Acute Pancreatitis (SAP), with the aim of developing more effective treatment strategies. Specifically, the study achieves this goal through the following four stages:

1. **Whole Exome Sequencing Analysis**: First, whole exome sequencing was performed on a large number of Acute Pancreatitis (AP) patient samples, identifying a specific variant (rs1326680184) located in the FCGBP gene, which is significantly associated with the occurrence of SIH.

2. **Serum ELISA Testing**: Further validation was conducted using serum enzyme-linked immunosorbent assay (ELISA) testing, confirming that the FCGBP variant indeed alters FCGBP protein levels, and this alteration is related to the occurrence of SIH.

3. **In Vivo Experiments**: In vivo experiments were conducted using Fcgbp gene knockdown mouse models, showing that reduced Fcgbp expression leads to more severe morphological changes in acute pancreatitis and a higher risk of hemorrhage.

4. **In Vitro Experiments**: In vitro experiments were performed by constructing FCGBP gene knockdown human vascular fibroblast models, demonstrating that downregulation of FCGBP expression can lead to vascular wall instability, resulting in vascular damage.

Additionally, the fourth stage compared the clinical characteristics of patients carrying the FCGBP variant with those who do not carry it. The results showed that patients carrying the variant have a higher risk of complications and poor prognosis. These findings help to reveal the potential mechanisms of SIH in SAP and may promote the development of effective treatment methods for the prognosis and critical care of acute pancreatitis.